« What Autism Epidemic? |
| Translation Needed »
May 4, 2011
GSK and Alli. Not Quite Working Out
Jim Edwards at Bnet has a report that GlaxoSmithKline doesn't seem to be doing quite as well selling Alli (orlistat) as they'd planned. This notwithstanding that their CEO, Andrew Witty, has said that they've had some interest from outside buyers for the franchise.
No, if you run the numbers, it's hard to see how GSK is making any money at all from the drug, especially if sales figures went down last year they way they'd gone down the year before. But then, it's not that the company is telling us those numbers, which might tell you something right there. How could anyone have predicted such a thing?
+ TrackBacks (0) | Category: Diabetes and Obesity
POST A COMMENT
- RELATED ENTRIES
- The Least Useful Element For Organic Chemistry?
- Piling On Andrew Witty
- Puma Update: The Roller Coaster Heads Down
- More Fluorinated Fun
- How Not to Handle Your Clinical Data
- An Alzheimer's IPO, Because Why Not
- A Glance Across the Literature
- Acetylene As Needed